Healthcare entity
Every one of those 2 sits in a single category, market-trends. Of the tracked stories, 2 of 2 also mention Novartis, the most common co-covered peer. The 13-day window averages about 1.1 stories each week. Source depth averages 3 original sources per story, versus 3.3 across the same-window beat baseline.
Last mentioned: Mar 10, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 2 sits in a single category, market-trends. Of the tracked stories, 2 of 2 also mention Novartis, the most common co-covered peer. The 13-day window averages about 1.1 stories each week. Source depth averages 3 original sources per story, versus 3.3 across the same-window beat baseline. Their average consequence score of 6 runs above the beat's 5.8 for that window. This profile follows 2 Healthcare stories mentioning Telix Pharmaceuticals across the period from February 26, 2026 to March 10, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 241 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Telix Pharmaceuticals. Shared-story counts are live from our verified record — not editorial picks.
Interim Analysis
Expected interim efficacy data from the larger global patient cohort.
Primary Objectives Met
Announcement that Part 1 successfully validated safety and dosimetry profiles.
Enrollment Milestone
Completion of patient enrollment for the Part 1 SELECT lead-in phase.
Study Initiation
Launch of the ProstACT Global Phase 3 study for mCRPC.
Telix Pharmaceuticals has successfully met the primary objectives for Part 1 of its global Phase 3 ProstACT study, validating the safety and dosimetry of its lead therapeutic candidate, TLX591. This milestone de-risks the antibody-based radiopharmaceutical program and clears the path for the trial's continued expansion in metastatic castration-resistant prostate cancer.
Source: sydneysun.com · wallstreet-online.de
Lantheus Holdings and Heron Therapeutics both reported mixed fourth-quarter results for the 2025 fiscal year, balancing immediate commercial headwinds with aggressive long-term guidance. Both companies introduced fiscal year 2026 outlooks, signaling a strategic shift toward post-2025 growth catalysts and pipeline diversification.
Source: Seeking Alpha · Seeking Alpha
Telix Pharmaceuticals is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
